



## Press Release

### **Astellas and Japanese Foundation for Cancer Research Announce Collaboration to Accelerate Translational and Clinical Oncology Research**

*- Initial collaboration will support projects of mutual interest and help accelerate advancement of Astellas' early-stage oncology pipeline -*

**TOKYO, April 2, 2025** - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Japanese Foundation for Cancer Research (Chairman: Toshio Asano, Ph.D., “JFCR”) today announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research.

The collaboration leverages Astellas' unique scientific, translational and clinical expertise and JFCR's strength as a world-class comprehensive cancer research center to quickly advance the development of novel treatments for patients with cancers that are resistant to current therapies.

Under the agreement, projects will be selected jointly based on shared interest and expertise. Selected projects will generate new translational and clinical data for Astellas' early-stage pipeline assets, which will be integrated with Astellas' own data to accelerate and refine these programs.

Through this collaboration, Astellas is committed to strengthening translational science and clinical research in order to deliver innovative new medicines. For JFCR, the collaboration provides early access to Astellas' pipeline, along with additional resources and expertise to bring these therapies to patients.

**Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer, Astellas**

“Collaborations with leading academic centers are at the heart of Astellas' strategy to deliver valuable medicines through scientific innovation. We are pleased to collaborate with JFCR, one of the largest and well-known cancer centers in Japan, to help advance our oncology pipeline. With a diverse set of early-stage oncology assets spanning multiple cutting-edge modalities, we are committed to delivering the next generation of therapies with outcomes that matter for patients. Through our partnerships, we can collectively enhance the insights and expertise that are critical

for accelerating the development of new and innovative treatments for patients in need.”

**Toshio Asano, Ph.D., Chairman, Japanese Foundation for Cancer Research**

“Bringing new treatments to patients is our mission, and we believe that partnership between industry and academia is essential to drive drug development. We are very pleased to partner with Astellas, which has an innovative pipeline, to accelerate translational research and development. Astellas, with its outstanding global pharmaceutical R&D capabilities, and JFCR, with its unique organization that integrates the hospital and research divisions to enhance drug discovery, will work together to fulfill our mission of “Achieving Better Cancer Control” and “Well-being of People Everywhere”

**About Astellas**

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at [www.astellas.com](http://www.astellas.com).

**About Japanese Foundation for Cancer Research (JFCR)**

The basic principle of JFCR is “Aiming to Improve the Well-being of People Everywhere by Achieving Better Cancer Control.” We aim to clarify the nature and individuality of cancer, contribute to cancer diagnosis, treatment, and prevention, and pioneer the frontiers of life science. To achieve this, we are actively promoting clinical trials for the development of new drugs, clinical research, and translational research that will lead to the development of new treatment and diagnostic methods, and are working to provide advanced cancer treatment to patients

**Astellas Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

**Astellas Pharma Inc.**

Corporate Communications

+81-3-3244-3201

**Japanese Foundation for Cancer Research**

Public Relations

+81-3-3570-0775

[ganken-pr@jfcrr.or.jp](mailto:ganken-pr@jfcrr.or.jp)

---